The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CTOR | -7.63% | N/A | N/A | -89% |
| S&P | +16% | +81.28% | +12.63% | +74% |
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.94M | 0.0% |
| Gross Profit | $3.15M | 0.0% |
| Gross Margin | 79.99% | 0.0% |
| Market Cap | $84.80M | 3.4% |
| Net Income | -$5,534.07K | 16.9% |
| EBITDA | -$5,252.28K | 17.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.30M | 6513695.5% |
| Accounts Receivable | $4.05M | 0.0% |
| Inventory | 22.6 | 57.4% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.80M | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -23.58% | 0.0% |
| Return On Invested Capital | -31.43% | -10.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$7,354.95K | 0.0% |
| Operating Free Cash Flow | -$7,354.95K | 0.0% |
| Metric | Q1 2024 | Q2 2024 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 54.86 | 85.29 | - | ||
| Price to Book | 1.61 | 8.73 | 4.48 | 1.86 | 4.37% |
| Price to Sales | 22.18 | - | |||
| Price to Tangible Book Value | -2.07 | -8.24 | -3.54 | -2.93 | 16.29% |
| Enterprise Value to EBITDA | -9.42 | -63.71 | -34.85 | -15.99 | 18.76% |
| Return on Equity | -47.4% | - | |||
| Total Debt | $3.80M | $3.80M | $3.80M | $3.80M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
